| Previous Close | 62.63 |
| Open | 62.54 |
| Bid | 61.60 x 100 |
| Ask | 61.99 x 100 |
| Day's Range | 62.50 - 62.90 |
| 52 Week Range | 57.18 - 66.80 |
| Volume | 7,780,922 |
| Avg. Volume | 8,843,779 |
| Market Cap | 171.14B |
| Beta | 0.97 |
| PE Ratio (TTM) | 39.88 |
| EPS (TTM) | 1.57 |
| Earnings Date | Jul 28, 2017 |
| Dividend & Yield | 1.88 (3.00%) |
| Ex-Dividend Date | 2017-06-13 |
| 1y Target Est | 69.70 |
- Business Wire•52 minutes ago
Merck Provides Update on Phase 3 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Merck , known as MSD outside the United States and Canada, today announced that the pivotal phase 3 KEYNOTE-040 trial investigating KEYTRUDA® , the company’s anti-PD-1 therapy, in previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma did not meet its pre-specified primary endpoint of overall survival . The safety profile observed in KEYNOTE-040 was consistent ...
Bloomberg•3 hours agoMerck, Samsung Accelerate a Biosimilar Price War
The days of high-priced knockoffs of biologic drugs are ending quickly.
- Reuters•4 hours ago
FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20)
Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.
